Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ryr7.8
Red Yeast Rice – Forschung
Hilft wahrscheinlich
106 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Red Yeast Rice scheint in 13 von 14 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1999–2026 mit einer typischen Studiengröße von 251 Teilnehmenden.
Basierend auf 106 Studien · 17 Meta-Analysen · 71 RCTs · 38,334 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
13geholfen1unklar· 92 weitere ohne bewertete Effektdaten
Nach Outcome
Cholesterol & lipidsReduziertes LDL-Cholesterin innerhalb von 4-8 Wochen · 4-8 weeks
Hilft wahrscheinlich82 Studien
Heart & blood pressureReduziertes LDL-Cholesterin innerhalb von 4-8 Wochen · 4-8 weeks
Hilft wahrscheinlich19 Studien
Safety profile
Hilft wahrscheinlich14 Studien
Glucose & metabolicSenkt das LDL-Cholesterin über natürliches Monacolin K · 4-8 weeks
Überwiegend Mechanismus / Beobachtung8 Studien
InflammationSignifikante Senkung des LDL-Cholesterins · 8-12 weeks
Überwiegend Mechanismus / Beobachtung6 Studien
Liver health
Zu wenige bewertete Studien1 Studie
Weight management
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 33 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
80%
über Studien hinweg
Untersuchte Personen
38k
typische Studie: 251 Personen
Stärkste Designs
88
17 gepoolt, 71 randomisiert
Zeigte Nutzen
93%
13/14 Studien
Wie lange Studien liefen
1–3 Monate
2
3+ Monate
3
Untersuchte Populationen
Patients with hyperlipidemia2
Adults2
Patients with hypercholesterolemia2
Hyperlipidemia patients2
Aktives Forschungsgebiet
35 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
199920122026
1Lipid concentrationsMeta-Analysen=4,838 · very large study2024
Einfach gesagt: Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
Hernandez AV et al. · Journal of dietary supplements (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Products with berberine alone had less robust effects on TC (MD -12.08 mg/dL [95%CI: -21.79 to -2.37]), LDL (MD -9.26 mg/dL [95%CI: -20.31 to 1.78]), and HDL (MD 1.38 mg/dL [95%CI: -1.27 to 4.03]) but TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23]).
Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
2Serum lipids, glucose, and hs-CRP improvementMeta-Analysen=1,050 · large study2021
Einfach gesagt: These changes are consistent with improved cardiometabolic health.
Cicero AFG et al. · Nutrients (2021)
Armolipid Plus® was well tolerated.
This meta-analysis demonstrates that dietary supplementation with Armolipid Plus® is associated with clinically meaningful improvements in serum lipids, glucose, and hs-CRP.
These changes are consistent with improved cardiometabolic health.
4Cholesterol reductionSystematische Übersichtn=769 · large study2024
Einfach gesagt: Low doses of monacolin K equal to 3mg/day exert potential cholesterol-lowering effects although the number of relative studies is limited.
Liasi E et al. · Semergen (2024)
Low doses of monacolin K equal to 3mg/day exert potential cholesterol-lowering effects although the number of relative studies is limited.
5Plasma lipids and glucoseMeta-Analysen=1,670 · large study2016
Einfach gesagt: Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Pirro M et al. · Pharmacological research (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Overall, WMDs were significant for the impact of NComb supplementation on plasma levels of total cholesterol (-26.15mg/dL, p<0.001), LDL-cholesterol (-23.85mg/dL, p<0.001), HDL-cholesterol (2.53mg/dL, p<0.001), triglycerides (-13.83mg/dL, p<0.001) and glucose (-2.59mg/dL, p=0.010).
NComb-induced amelioration of lipid profile was not affected by duration of supplementation nor by baseline lipid levels; conversely, a greater glucose-lowering effect of NComb was found with higher baseline glucose levels and longer durations of supplementation.
9Safety outcomesMeta-Analysen=61 · small study2024
Einfach gesagt: The evidence examined in this study suggests that RYR preparations are safe; however, the credibility of the evidence was not high.
Ma ZY et al. · Journal of integrative medicine (2024)
Based on A MeaSurement Tool to Assess Systematic Reviews version 2, 3 (20%) and 12 (80%) of these meta-analyses had low and critically low confidence, respectively.
The other 46 (75.4%) associations showed no significant difference between the use of RYR preparations and control treatments.
Regarding the credibility of the evidence, 21 (34.4%), 34 (55.7%) and 6 (9.8%) associations showed moderate, low and very low credibility, respectively.
Einfach gesagt: In conclusion, this comprehensive article and meta-analysis showed that RYR significantly decreases TC, TG, and LDL-C as well as increases HDL-C.
Rahmani P et al. · Expert review of clinical pharmacology (2023)
In conclusion, this comprehensive article and meta-analysis showed that RYR significantly decreases TC, TG, and LDL-C as well as increases HDL-C.
Einfach gesagt: This meta-analysis indicated that RYR extract in MI patients with borderline hypercholesterolemia is associated with improved cardiovascular outcomes and lipid profiles.
Sungthong B et al. · Scientific reports (2020)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
RYR extract (1,200 mg/day) reduced nonfatal MI (risk ratio (RR) = 0.42, 95% CI 0.34 to 0.52), revascularization (RR = 0.58, 95% CI 0.48 to 0.71), and sudden death (RR = 0.71, 95% CI 0.53 to 0.94).
Follow-up periods ranged from 4 weeks - 4.5 years and the studies were overall of high quality with low risk of bias.
This meta-analysis indicated that RYR extract in MI patients with borderline hypercholesterolemia is associated with improved cardiovascular outcomes and lipid profiles.
17LDL and total cholesterol reductionMeta-Analysen=1,012 · large study2022
Einfach gesagt: RYR at 200-4800 mg daily appears to be a safe and effective treatment for hyperlipidemia, effectively regulating blood lipid levels with an exceptional impact on TG.
Li P et al. · Frontiers in Pharmacology (2022)
Groß Nutzen
← SchlechterKein EffektBesser →
Compared with nutraceutical, RYR significantly reduced TC (MD, -17.80; 95% CI, -27.12 to -8.48; p = 0.0002) and LDL-C (MD, -14.40; 95% CI, -22.71 to -6.09; p = 0.0007).
In comparison to statins, RYR was more effective in lowering TG and comparable in lowering LDL-C and elevating HDL-C.
Whether alone or in combination, RYR did not increase the risk of adverse events in patients with hyperlipidemia.
Einfach gesagt: This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
Millán J et al. · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The effect size (relative change from baseline (%)) was -1.3 (9.9%) for total cholesterol, -1.17 (-13.7%) for LDL-c, +0.17 (+3.7%) for HDL-c and -0.24 (-7.0%) for Triglycerides.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
Einfach gesagt: A methodology for the calculation of the CLCI is presented, alongside potential applications in food labeling, clinical guidance, and dietary planning.
Jacobo-Velázquez DA. · Nutrients (2025)
Strategies for the design of next-generation cholesterol-lowering foods are discussed, such as combining multiple bioactives for synergistic effects, personalized nutrition approaches, and novel food processing techniques to enhance bioavailability.
Building on these strategies, the CLCI is then proposed as a practical scoring system, analogous to the glycemic index for blood sugar, that integrates the evidence-based potency of ingredients, effective dosing, and synergistic interactions into a single metric.
A methodology for the calculation of the CLCI is presented, alongside potential applications in food labeling, clinical guidance, and dietary planning.